期刊文献+

阿托伐他汀对冠状动脉微栓塞后心肌炎症的影响 被引量:4

Roles of atrovastatin in the myocardial inflammation following coronary microembolization
下载PDF
导出
摘要 目的 探讨阿托伐他汀干预治疗对冠状动脉微栓塞(CME)后心肌炎症的影响.方法 48只清洁级雄性SD大鼠经左心室内注射自体微血栓,同时短暂夹闭主动脉,建立大鼠CME模型后,随机分为未治疗组及阿托伐他汀(Atrovastatin)干预组,于术后7 d处死.HE染色观察梗死心肌,免疫组织化学染色及Western blot检测肿瘤坏死因子α(TNF-α)、白介素6(IL-6)及细胞间黏附因子1(ICAM-1)等炎症因子在心肌中表达的变化.结果 阿托伐他汀可轻度减少梗死面积,显著抑制CME后心肌中白细胞浸润及TNF-α、IL-6、ICAM-1 蛋白表达(P均〈0.05).结论 阿托伐他汀能显著抑制CME后心肌炎症反应. Objective To investigate the roles of atrovastatin in the myocardial inflammation following coronary microembolization. Methods CME model in 48 rats was created by injection homologous microthrombotic particle suspension into left ventricle when clamping the ascending aorta. The CME rats were randomized to untreated group and atrovastatin treated group (n=24 respectively). The rats were sacrificed on day 7 post-operationally. The morphological characteristics were evaluated in sections with HE staining and the protein expressions of TNF-~, IL-6 and ICAM-1 were semi-quantitatively analyzed by immunohistochemistry and Western blot. Results Atrovastatin slightly reduced infarct size and significantly suppressed inflammatory cell infiltration and the protein expression of TNF-α, IL-6 and ICAM-1 (P〈0.05). Conclusion Atrovastatin markedly suppressed the TNF-α, IL-6 protein expression and effectively ameliorated myocardial inflammation.
出处 《中国心血管病研究》 CAS 2014年第1期56-58,95,共4页 Chinese Journal of Cardiovascular Research
基金 南京军区医学科技创新基金(项目编号:09MA104)
关键词 冠脉微栓塞 肿瘤坏死因子α 白介素6 细胞间黏附因子1 他汀 Coronary mieroerabolization TNF-α IL-6 ICAM-1 Statins
  • 相关文献

参考文献10

  • 1Heusch G,Kleinbongard P,Bose D. Coronary microembolization:from bedside to bench and back to bedside[J].{H}CIRCULATION,2009.1822-1836.
  • 2Liuzzo G,Santamaria M,Biasucci LM. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocyte via nuclear factor kappa-B activation[J].{H}Journal of the America College of Cardiology,2007.185-194.
  • 3吴志婷,梅拥军,曹平良,曾黎峰,尹秋林,盛国太,葛郁芝.炎性因子与急性冠状动脉综合征相关性研究[J].中国心血管病研究,2008,6(10):732-734. 被引量:8
  • 4Skyschally A,Haude M,Dorge H. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization[J].{H}CIRCULATION,2004.2337-2342.
  • 5王长华,胡大一.他汀类药物的抗炎效应[J].国外医学(心血管疾病分册),2004,31(4):227-229. 被引量:41
  • 6Li S,Zhong S,Zeng K. Blockade of NF-KB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats[J].{H}Basic Research in Cardiology,2010.139-150.
  • 7李淑梅,陈良龙,曾凯,吴进寿.炎症因子在大鼠冠状动脉微栓塞后心肌组织中的表达及NF-κB抑制剂对其的影响[J].第二军医大学学报,2011,32(8):851-855. 被引量:4
  • 8Michalek A. Results of ARMYDA-ACS trial show good outcome of 80 mg atorvastatin pretreatment in patients with acute coronary syndromes undergoing early percutaneous coronary intervention[J].{H}Kardiologia Polska,2007.851-852.
  • 9Patti G,Pasceri V,Colonna G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDA-ACS randomized trial[J].{H}Journal of the America College of Cardiology,2007.1272-1278.
  • 10郑刚,张承宗.解读急性冠状动脉综合征他汀类药物治疗作用的临床证据(一)[J].中国心血管病研究,2004,2(6):406-409. 被引量:8

二级参考文献55

  • 1曹平良,葛郁芝,曾黎峰,盛国泰,吴志婷.髓过氧化物酶与冠状动脉内不稳定斑块的相关性研究[J].中华心血管病杂志,2005,33(9):835-835. 被引量:4
  • 2李淑梅,孙旭东,孙伏清,曾凯,吴进寿,罗顺祥,陈良龙.大鼠冠状动脉微栓塞后细胞间黏附分子1在心肌中的表达及意义[J].中华老年医学杂志,2007,26(4):285-288. 被引量:6
  • 3[1]Braunwald E, Antman EM, Beasley JW. ACC/AHA guidelines for the ranagement of patient with unstable angina and non ST segment elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patient with Unstable Angina)[J ]. J Am Coll Cardiol, 2000,36: 970 - 1062
  • 4[3]The Scandinavian Simvastatin Surrival Study Group.Randomized trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Surrival Study (4s) [ J ]. Lancet, 1994,344:1383 - 1389
  • 5[4]Ridket PM, Rifai N, Pfeffer MA, et al. Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesteterol levels. Cholesterol and Recurrent Events(CARE)Investigators[ J ]. Circulation, 1998,98: 839 - 844
  • 6[5]The Long- term Intervention with Pravastatin in Ischemic Disease Study Group. Prevention of cardiovascular events and a broad range of initial cholesterol levels[J ]. N Engl J Med, 1998,339:1349 - 1357
  • 7[6]West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) [J ]. Circulation, 1998,97:1440 -1445
  • 8[7]Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels; results of AFCAPS/Tex CAPS[ J ]. JAMA, 1998,279:1615 - 1622
  • 9[9]Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling ( PPP ) project [ J ]. Circulation,2000,102:1893 - 1900
  • 10[10]Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: A randomized clinic trial [ J ]. JAMA, 2001,285:1711 - 1718

共引文献54

同被引文献64

  • 1刘健,王昭,王伟民.2012欧洲ST段抬高急性心肌梗死患者管理指南解读[J].中国医学前沿杂志(电子版),2013,5(2):55-60. 被引量:16
  • 2国家药典委员会.中华人民共和国药典[M].北京:化学工业出版社,2005.114.
  • 3汪文涛,李文莉.湖南省中药饮片炮制规范[M].长沙:湖南科学技术出版社,2010.
  • 4Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases[J]. Med Hypotheses, 2004,62(4):499-506.
  • 5European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) [J]. Eur Heart J, 2011,32(14):1769-1818.
  • 6Ostadal P, Alan D, Hajek P, et al. The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction[J]. Mol Cell Biochem, 2003,246(1-2):45-50.
  • 7Gore JM, Goldberg RJ, Matsumoto AS, et al. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction[J]. Am J Cardiol, 1984,54(7):722-725.
  • 8Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL[J]. J Clin Invest, 2007,117(3):746-756.
  • 9Kotseva K, Wood D, De Backer G, et al. EUROASPIRE Ⅲ: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries[J]. Eur J Cardiovasc Prev Rehabil, 2009,16(2):121-137.
  • 10De Luca G, Navarese EP, Cassetti E, et al. Meta-analysis of randomized trials of glycoprotein Ⅱb/Ⅲa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy[J]. Am J Cardiol, 2011,107(2):198-203.

引证文献4

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部